Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (000766.SZ) Latest Company News

Oct 26, 2026, 07:50 UTC
Tonghua Golden-Horse Pharmaceutical reported revenue of 737 million yuan and net profit of 1.9722 million yuan for the first three quarters of 2026.
Source:
- finance.sina.cn
Oct 26, 2026, 07:50 UTC
Tonghua Golden-Horse Pharmaceutical reported third-quarter 2026 revenue of 179 million yuan, down 25.94% year over year, and a net loss of 5.1324 million yuan.
Source:
- finance.sina.cn
Sep 23, 2026, 07:17 UTC
Tonghua Golden-Horse Pharmaceutical obtained a drug registration certificate for its new drug amvatinide succinate tablets for the treatment of mild to moderate Alzheimer's disease symptoms.
Source:
- finance.sina.cn
Aug 24, 2026, 09:39 UTC
Tonghua Jinma signed a comprehensive strategic cooperation agreement with Xuanwu Hospital of Capital Medical University to advance clinical research on its Alzheimer's drug and stroke pipeline.
Source:
- finance.sina.cn
Aug 20, 2026, 07:44 UTC
Tonghua Golden-Horse Pharmaceutical reported H1 2026 revenue of 557 million yuan, down 14.28% year-on-year, and net profit of 7.1046 million yuan, down 57.72% year-on-year.
Source:
- finance.sina.cn
Aug 6, 2026, 10:47 UTC
Tonghua Jinma's wholly-owned subsidiary Guilin Jinma signed a letter of intent to acquire a controlling stake in Bayajia Pharmaceutical on August 6, 2026.
Source:
- finance.sina.cn
Jul 14, 2026, 03:32 UTC
China's National Medical Products Administration approved Tonghua Jinma Pharmaceutical Group's new drug Succinic Acid Anweiacridine Tablets (brand name Maoantong) for marketing.

000766.SZ

Tonghua Golden-Horse Pharmaceutical reported revenue of 737 million yuan and net profit of 1.9722 million yuan for the first three quarters of 2026.

Tonghua Golden-Horse Pharmaceutical reported third-quarter 2026 revenue of 179 million yuan, down 25.94% year over year, and a net loss of 5.1324 million yuan.

Tonghua Golden-Horse Pharmaceutical obtained a drug registration certificate for its new drug amvatinide succinate tablets for the treatment of mild to moderate Alzheimer's disease symptoms.

Tonghua Jinma signed a comprehensive strategic cooperation agreement with Xuanwu Hospital of Capital Medical University to advance clinical research on its Alzheimer's drug and stroke pipeline.

Tonghua Golden-Horse Pharmaceutical reported H1 2026 revenue of 557 million yuan, down 14.28% year-on-year, and net profit of 7.1046 million yuan, down 57.72% year-on-year.

Tonghua Jinma's wholly-owned subsidiary Guilin Jinma signed a letter of intent to acquire a controlling stake in Bayajia Pharmaceutical on August 6, 2026.

China's National Medical Products Administration approved Tonghua Jinma Pharmaceutical Group's new drug Succinic Acid Anweiacridine Tablets (brand name Maoantong) for marketing.